Company MDxHealth SA

Equities

MDXH

BE0974461940

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-23 pm EDT			5-day change	1st Jan Change
2.77 ^USD	0.00%		-1.60%	-29.70%

May. 01	MDxHealth SA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 01	Transcript : MDxHealth SA, Q1 2024 Earnings Call, May 01, 2024

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Companyâs tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

Number of employees: 300

USD in Million	2022	Weight	2023	Weight	Delta
Clinical Laboratory Service Testing 99.7 %	37	99.8 %	70	99.7 %	+89.27%
Royalties and Other 0.3 %	0	0.2 %	0	0.3 %	+256.25%

USD in Million	2022	Weight	2023	Weight	Delta
United States 99.3 %	37	99.2 %	70	99.3 %	+89.59%
Europe 0.7 %	0	0.7 %	0	0.7 %	+71.84%
Rest of the World 0.0 %	0	0.0 %	0	0.0 %	0.00%

Managers	Title	Age	Since
Michael K. McGarrity CEO	Chief Executive Officer	62	19-02-17
Ron Kalfus DFI	Director of Finance/CFO	50	19-07-21
Miriam Reyes COO	Chief Operating Officer	-	-
Joseph Sollee CMP	Compliance Officer	60	03-01-09
Harry Rentrop PRN	Corporate Officer/Principal	-	-
John Bellano PRN	Corporate Officer/Principal	56	19-06-18

Members of the board	Title	Age	Since
Donnie Hardison BRD	Director/Board Member	74	21-09-28
Eric Bednarski BRD	Director/Board Member	52	20-07-29
Hilde Windels BRD	Director/Board Member	59	17-10-31
Michael K. McGarrity CEO	Chief Executive Officer	62	19-02-17
Koen Hoffman CHM	Chairman	56	17-12-31
Regine Slagmulder BRD	Director/Board Member	58	19-12-31
Lieve Verplancke BRD	Director/Board Member	65	17-05-25

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	27,288,093	25,630,246 ( 93.92 %)	0	93.92 %

Name	Equities	%	Valuation
MVM Partners LLP 16.68 %	4,550,458	16.68 %	11 M $
MVM Partners LLC 16.68 %	4,550,457	16.68 %	11 M $
Bleichroeder LP 14.21 %	3,878,333	14.21 %	10 M $
Valiance Asset Management Ltd. 7.670 %	2,093,109	7.670 %	5 M $
Rudi Mariën 4.370 %	1,192,359	4.370 %	3 M $
Bleichroeder LP 1.539 %	420,000	1.539 %	1 M $
Perkins Capital Management, Inc. 1.522 %	415,225	1.522 %	1 M $
Hood River Capital Management LLC 1.213 %	330,879	1.213 %	817 271 $
BNP Paribas Asset Management Belgium SA 0.5169 %	141,058	0.5169 %	348 413 $
SEI INVESTMENTS COMPANY 0.3122 %	85,189	0.3122 %	210 417 $

MDxHealth SA

CAP Business Center Zone Industrielle des Hauts-Sarts

4040, Herstal

+32 4 257 70 21

http://www.mdxhealth.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.77 USD

Average target price

7.25 USD

Spread / Average Target

+161.73%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MDXHEALTH SA	-29.70%	75.59M
MODERNA, INC.	+64.92%	62.59B
IQVIA HOLDINGS INC.	-1.85%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	19.09B
BIO-TECHNE CORPORATION	+4.21%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.26B
MEDPACE HOLDINGS, INC.	+27.42%	12.05B

Other Biotechnology & Medical Research